-
Product Insights
New![]()
PG Silesia Coal Mine
The PG Silesia Coal Mine is a coal mine in Poland. It is currently in operation. Empower your strategies with our PG Silesia Coal Mine report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to...
-
Product Insights
New![]()
Sir Adam Beck PGS
Sir Adam Beck PGS is a Hydro project located in Ontario, Canada. The project is owned by Ontario Power Generation Inc. The project came online in 1957. Empower your strategies with our Sir Adam Beck PGS report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be...
-
Product Insights
New![]()
Huron (PG&E) Solar Park
Huron (PG&E) Solar Park is a solar PV project located in California, United States. The project is owned by Pacific Gas and Electric Co and was developed by Cupertino Electric Inc. The project came online in 2012. Empower your strategies with our Huron (PG&E) Solar Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding...
-
Product Insights
New![]()
Huron (PG&E) Solar Park – 1
Huron (PG&E) Solar Park – 1 is a solar PV project located in California, United States. The project is owned by Pacific Gas and Electric Co and was developed by Cupertino Electric Inc. The project came online in 2013. Empower your strategies with our Huron (PG&E) Solar Park – 1 report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day...
-
Company Insights
New![]()
Innovation and Patenting activity of PG&E Corp Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of PG&E Corp Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ropivacaine in Post-Operative Pain
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Ropivacaine in Post-Operative PainDrug Details:Ropivacaine (CPL-01) is under development for the treatment of acute post operative...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Dordaviprone in Paraganglioma (Glomus Jugulare Tumor)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Dordaviprone in Paraganglioma (Glomus Jugulare Tumor) Drug Details: ONC-201 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Dordaviprone in Glioma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Dordaviprone in Glioma Drug Details: ONC-201 is under development for the treatment of high-grade glioma...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Dordaviprone in Recurrent Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Dordaviprone in Recurrent Glioblastoma Multiforme (GBM) Drug Details: ONC-201 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Dordaviprone in Pheochromocytoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Dordaviprone in Pheochromocytoma Drug Details: ONC-201 is under development for the treatment of high-grade glioma...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.